Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
NCT Number: NCT01519596
This is a randomized clinical trial that studies symptom-adapted physical activity intervention in minimizing physical function decline in older patients with acute myeloid leukemia (AML) undergoing chemotherapy. Physical activity may help decrease functional impairment and improve the quality of life in patients with AML undergoing chemotherapy.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Winston-Salem, North Carolina, 27157, United States
PRIMARY OBJECTIVES:
I. To evaluate the feasibility of conducting a symptom-adapted, randomized behavioral intervention designed to improve physical function in older adults receiving chemotherapy for AML.
II. To estimate the effect size of the physical activity intervention on change in an objective measure of physical function, SPPB (short physical performance battery).
SECONDARY OBJECTIVES:
I. To estimate the effects of the physical activity intervention on self-reported physical function, health-related quality of life, and symptoms (depression, distress, fatigue).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
ARM II: Patients undergo usual care for 4 weeks.
After completion of study treatment, patients are followed up every two weeks for two months and then monthly until week 24.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ancillary studies
Other names: quality of life assessment
Receive lifestyle-related counseling
Other names: counseling and communications studies
Undergo physical activity intervention
Receive educational materials
Other names: intervention, educational
Undergo usual care
Time frame: Approximately 4 weeks
Number of exercise sessions completed, dropout rates, completion rates of the physical function measures, and completion rates of questionnaires will be recorded. Adherence will be defined as completion of at least 60% of the offered sessions.
Time frame: Approximately 4 weeks
Characterized using mixed model analysis of variance (ANOVA) with an appropriate error structure to account for the correlated nature of the data.
Time frame: Approximately 4 weeks
Time frame: Approximately 24 weeks
Wake Forest University Health Sciences
Other
Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01588015
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Duarte, California, United States
View Trial DetailsNCT02122081
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Columbus, Ohio, United States
View Trial DetailsNCT00089011
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Salt Lake City, Utah, United States
View Trial DetailsNCT00014235
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
Tucson, Arizona, United States
View Trial Details